08 Jan Cellectar reporting favorable results from clinical trial
Cellectar Biosciences is reporting patients in a recent clinical trial of its cancer therapy medication are surviving longer.
The first four study groups of the Madison company’s ongoing Phase 1 clinical trial included 15 patients who had been previously treated with five lines of therapy on average. Each patient in those four study groups received a single 30-minute infusion of CLR 131, Cellectar’s cancer treatment drug.
Results from that research show those patients had a median overall survival rate of 22 months, which CEO and President James Caruso says is “very encouraging.”
“We believe extending [survival] with a more patient-friendly dosing regimen provides both a distinctive product profile and the potential to provide beneficial patient outcomes even in later lines of therapy,” Caruso said.
Sorry, the comment form is closed at this time.